​

Moderna (MRNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRNA Stock Forecast

Moderna (MRNA) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $35.67, with a high of $63.00 and a low of $17.00. This represents a -36.27% decline from the last price of $55.97.

- $30 $60 $90 $120 $150 High: $63 Avg: $35.67 Low: $17 Last Closed Price: $55.97

MRNA Stock Rating

Moderna stock's rating consensus is Hold, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (29.63%), 15 Hold (55.56%), 4 Sell (14.81%), and 0 Strong Sell (0.00%).

Hold
Total 27 0 4 15 8 Strong Sell Sell Hold Buy Strong Buy

MRNA Price Target Upside V Benchmarks

TypeNameUpside
StockModerna-36.27%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts6720
Avg Price Target$35.50$35.29$32.05
Last Closing Price$55.97$55.97$55.97
Upside/Downside-36.57%-36.95%-42.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2612181224
Feb, 2612181224
Jan, 2623161224
Dec, 2514151223
Nov, 2523151324
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 03, 2026Andrew TsaiJefferies$37.00$49.83-25.75%-33.89%
Feb 17, 2026Luca IssiRBC Capital$30.00$42.54-29.48%-46.40%
Feb 17, 2026Cory KasimovEvercore ISI$35.00$43.19-18.96%-37.47%
Feb 17, 2026Bernstein$45.00$42.236.56%-19.60%
Feb 16, 2026UBS$36.00$42.23-14.75%-35.68%
Feb 16, 2026Morgan Stanley$30.00$42.23-28.96%-46.40%
Jan 06, 2026UBS$34.00$35.66-4.66%-39.25%
Dec 12, 2025Morgan Stanley$28.00$29.90-6.35%-49.97%
Dec 12, 2025Jefferies$30.00$29.621.28%-46.40%
Nov 21, 2025Luca IssiRBC Capital$25.00$23.108.23%-55.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 03, 2026JefferiesHoldHoldhold
Feb 23, 2026Piper SandlerOverweightOverweighthold
Feb 17, 2026RBC CapitalSector PerformSector Performhold
Feb 17, 2026BernsteinMarket PerformMarket Performhold
Feb 16, 2026UBSNeutralNeutralhold
Feb 16, 2026CitigroupNeutralNeutralhold
Jan 30, 2026Leerink PartnersUnderperformUnderperformhold
Jan 29, 2026Cowen & Co.HoldHoldhold
Jan 19, 2026CitigroupNeutralNeutralhold
Jan 12, 2026BMO CapitalMarket PerformBuyupgrade

Financial Forecast

EPS Forecast

$-20 $-9 $2 $13 $24 $35 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$30.31$21.26$-12.34$-9.27$-7.26---
Avg Forecast$27.27$21.26$-13.46$-9.12$-8.91$-6.91$-4.90$-2.64
High Forecast$34.01$25.98$-11.27$-8.03$-6.72$-2.06$1.34$-1.89
Low Forecast$22.35$17.34$-15.66$-10.29$-10.29$-8.49$-7.46$-3.35
Surprise %11.15%--8.32%1.64%-18.52%---

Revenue Forecast

$0 $5B $10B $15B $20B $25B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$17.74B$18.88B$6.85B$3.20B$1.94B---
Avg Forecast$18.02B$19.13B$6.47B$3.23B$2.56B$3.09B$4.14B$5.30B
High Forecast$21.45B$22.40B$6.84B$3.35B$3.16B$3.16B$4.27B$6.40B
Low Forecast$15.52B$16.42B$6.17B$3.15B$2.27B$3.02B$4.01B$4.14B
Surprise %-1.57%-1.33%5.92%-0.83%-24.18%---

Net Income Forecast

$-10B $-4B $2B $8B $14B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.20B$8.36B$-4.71B$-3.56B$-2.82B---
Avg Forecast$11.55B$13.15B$-4.71B$-3.50B$-3.53B$-2.71B$-1.97B$-1.01B
High Forecast$13.86B$15.78B$-3.77B$-3.07B$-2.57B$-787.35M$510.78M$-721.88M
Low Forecast$9.24B$10.52B$-5.66B$-3.93B$-3.93B$-3.24B$-2.85B$-1.28B
Surprise %5.65%-36.42%-1.80%-20.07%---

MRNA Forecast FAQ

Is Moderna stock a buy?

Moderna stock has a consensus rating of Hold, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 15 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Moderna is a neutral investment for most analysts.

What is Moderna's price target?

Moderna's price target, set by 27 Wall Street analysts, averages $35.67 over the next 12 months. The price target range spans from $17 at the low end to $63 at the high end, suggesting a potential -36.27% change from the previous closing price of $55.97.

How does Moderna stock forecast compare to its benchmarks?

Moderna's stock forecast shows a -36.27% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Moderna over the past three months?

  • March 2026: 4.17% Strong Buy, 8.33% Buy, 75.00% Hold, 4.17% Sell, 8.33% Strong Sell.
  • February 2026: 4.17% Strong Buy, 8.33% Buy, 75.00% Hold, 4.17% Sell, 8.33% Strong Sell.
  • January 2026: 8.33% Strong Buy, 12.50% Buy, 66.67% Hold, 4.17% Sell, 8.33% Strong Sell.

What is Moderna’s EPS forecast?

Moderna's average annual EPS forecast for its fiscal year ending in December 2026 is $-6.91, marking a -4.82% decrease from the reported $-7.26 in 2025. Estimates for the following years are $-4.9 in 2027, and $-2.64 in 2028.

What is Moderna’s revenue forecast?

Moderna's average annual revenue forecast for its fiscal year ending in December 2026 is $3.09B, reflecting a 58.76% increase from the reported $1.94B in 2025. The forecast for 2027 is $4.14B, and $5.3B for 2028.

What is Moderna’s net income forecast?

Moderna's net income forecast for the fiscal year ending in December 2026 stands at $-2.713B, representing a -3.85% decrease from the reported $-2.822B in 2025. Projections indicate $-1.966B in 2027, and $-1.01B in 2028.